Efficacy and Safety of Bulevirtide (BLV) Therapy in HDV Chronic Hepatitis (CHD) in Italy

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

April 30, 2023

Study Completion Date

May 31, 2023

Conditions

Hepatitis D

Interventions

DRUG

Bulevirtide

dose of 2 mg/day subcutaneously

Trial Locations (1)

Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy., Milan

All Listed Sponsors

lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER